AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Inmune Bio, Inc. Director's Dealing 2019

Aug 12, 2019

34518_dirs_2019-08-12_5f87109e-2b4e-4ef6-ad01-b1c2cf6c55fb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Inmune Bio, Inc. (INMB)
CIK: 0001711754
Period of Report: 2019-08-09

Reporting Person: Tesi Raymond Joseph (Director, President & CEO, 10% Owner)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2019-08-09	Common Stock	P	100	$7.20	Acquired	1537033	Direct
2019-08-09	Common Stock	P	900	$7.1431	Acquired	1537933	Direct
2019-08-09	Common Stock	P	1000	$6.9095	Acquired	1538933	Direct

Footnotes

F1: The Reporting Person purchased an aggregate of 2,000 shares of the Registrant's common stock on August 9, 2019 in two open market transactions.